Keros Therapeutics is dedicated to developing innovative therapies targeting dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The company focuses on shifting treatment paradigms for patients with various disorders, offering a distinctive approach by leveraging cutting-edge research and development in this area.
Keros is a company focused on developing differentiated product candidates to alter TGF-β signaling, aiming to improve blood cell growth, repair, and maintenance, and reduce the progression of disease. They prioritize diversity, equity, and inclusion in their workplace.
Keros Therapeutics is dedicated to developing innovative therapies targeting dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The company focuses on shifting treatment paradigms for patients with various disorders, offering a distinctive approach by leveraging cutting-edge research and development in this area.
Integritus Healthcare, Inc.